NVAX - Novavax, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Novavax, Inc.

20 Firstfield Road
Gaithersburg, MD 20878
United States
240-268-2000
http://www.novavax.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees373

Key Executives

NameTitlePayExercisedYear Born
Mr. Stanley Charles ErckPres, CEO & Director649.04kN/A1948
Mr. John Joseph TrizzinoSr. VP, Chief Bus. Officer, CFO & Treasurer439.08kN/A1960
Mr. John A. Herrmann IIISr. VP, Gen. Counsel & Corp. Sec.425.02kN/A1966
Dr. Gregory M. GlennPres of R&D550.27kN/A1954
Ms. Erika S. TrahanSr. Mang. of Investor & PRN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Novavax, Inc., together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The company's lead vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein recombinant nanoparticle vaccine with aluminum phosphate as an adjuvant that is in Phase III clinical trial to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in Phase II clinical trial for treating seasonal influenza in older adults. Its lead adjuvant is Matrix-M that is used to enable a vaccine to enhance the amplitude of the immune response and qualitatively change it, and the immune systems attack against microorganisms, as well as allows immunization with much lower doses of antigen. The company also develops RSV F vaccine for older adults in Phase II clinical trial, and healthy children between two and six years of age in Phase I clinical trial. In addition, it develops nanoparticle vaccine candidates for clinic testing against ebola virus in Phase I clinical trial, as well as MERS coronavirus in animals; and combination respiratory vaccine to protect against influenza and RSV. The company has a clinical development agreement with Bill & Melinda Gates Foundation. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.

Corporate Governance

Novavax, Inc.’s ISS Governance QualityScore as of July 29, 2019 is 8. The pillar scores are Audit: 5; Board: 8; Shareholder Rights: 7; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.